Qatar v. Ecuador to kick off FIFA World Cup 2022™ on 20 NovemberRead more Webb Fontaine Announces Launch of Niger National Single Window (NNSW) to Bolster TradeRead more Ethiopia: Loan from United Nations Fund Allows Food and Agriculture Organization (FAO) to Scale Up Fertilizers for Farmers in TigrayRead more How Choosing the Right Printer Helps Small Businesses and Content Creators to Save Time, Maximise Productivity and Achieve GrowthRead more Eritrea: World Breastfeeding WeekRead more Eritrean community festival in Scandinavian countriesRead more IOM: Uptick in Migrants Heading Home as World Rebounds from COVID-19Read more Network International & Infobip to offer WhatsApp for Business Banking Services to Financial Institution Clients across AfricaRead more Ambassador Jacobson Visits Gondar in the Amhara Region to Show Continued U.S. Support for the Humanitarian and Development Needs of EthiopiansRead more Voluntary Repatriation of Refugees from Angola to DR Congo ResumesRead more

Pfizer looks for conditional EU authorization for COVID-19 drug

show caption
AFP Photo
Print Friendly and PDF

Jan 11, 2022 - 06:34 AM

BRUSSELS (AA) – The European Medicines Agency (EMA) said on Monday that it has begun evaluating an application by Pfizer for its anti-coronavirus drug Paxlovid.

“EMA has started evaluating an application for a conditional marketing authorization for the oral antiviral medicine Paxlovid,” the EU regulator said in a statement.

The statement said that the regulator could deliver its assessment within weeks since it had already carried out a preliminary review based on laboratory, animal, and clinical studies.

Following EMA’s recommendation, the European Commission would officially give the marketing authorization.

The medicine reduces the ability of the virus to multiply in the body.

By treating adults and adolescents with mild-to-moderate symptoms of COVID-19, the drug can lower the risk of developing severe illness and hospitalization.

LMBCHEALTH.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.